(SENS) Senseonics Holdings - Ratings and Ratios
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US81727U1051
SENS: Eversense, Eversense XL, Eversense E3
Senseonics Holdings, Inc., a medical technology company, specializes in the development and manufacturing of continuous glucose monitoring (CGM) systems designed to improve diabetes management. The companys flagship products, Eversense, Eversense XL, and Eversense E3, are implantable CGM systems that measure glucose levels through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a user-friendly app for real-time monitoring and data management. These systems are differentiated by their extended wear times, with Eversense XL offering up to 180 days of continuous use, and Eversense E3 designed for 60 days, catering to different patient preferences and clinical needs.
Founded in 1996 and headquartered in Germantown, Maryland, Senseonics has established itself as a pioneer in the CGM space, particularly with its focus on implantable technology. The company distributes its products through a network of healthcare providers, distributors, and strategic partners, ensuring access to patients globally. Senseonics technology integrates advanced sensor design, proprietary fluorescence-based chemistry, and mobile health software, providing users with accurate and reliable glucose data to manage their diabetes effectively.
3-Month Forecast: Based on
Additional Sources for SENS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SENS Stock Overview
Market Cap in USD | 400m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 2016-03-17 |
SENS Stock Ratings
Growth 5y | -15.0% |
Fundamental | -19.9% |
Dividend | 0.0% |
Rel. Strength Industry | 5.08 |
Analysts | 3.25/5 |
Fair Price Momentum | 0.56 USD |
Fair Price DCF | - |
SENS Dividends
No Dividends PaidSENS Growth Ratios
Growth Correlation 3m | 50.6% |
Growth Correlation 12m | 9.9% |
Growth Correlation 5y | -33.2% |
CAGR 5y | -3.53% |
CAGR/Max DD 5y | -0.04 |
Sharpe Ratio 12m | -1.16 |
Alpha | -13.19 |
Beta | 2.31 |
Volatility | 123.32% |
Current Volume | 2706.3k |
Average Volume 20d | 7443.9k |
As of March 16, 2025, the stock is trading at USD 0.59 with a total of 2,706,263 shares traded.
Over the past week, the price has changed by -8.26%, over one month by -52.17%, over three months by +34.61% and over the past year by +6.01%.
Neither. Based on ValueRay Fundamental Analyses, Senseonics Holdings is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -19.93 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SENS as of March 2025 is 0.56. This means that SENS is currently overvalued and has a potential downside of -5.08%.
Senseonics Holdings has received a consensus analysts rating of 3.25. Therefor, it is recommend to hold SENS.
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, SENS Senseonics Holdings will be worth about 0.6 in March 2026. The stock is currently trading at 0.59. This means that the stock has a potential upside of +8.47%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 1.6 | 171.2% |
Analysts Target Price | 2.3 | 281.4% |
ValueRay Target Price | 0.6 | 8.5% |